169 related articles for article (PubMed ID: 26250892)
1. Prednisolone does not affect direct-acting antivirals against hepatitis C, but inhibits interferon-alpha production by plasmacytoid dendritic cells.
de Ruiter PE; Boor PP; de Jonge J; Metselaar HJ; Tilanus HW; Ijzermans JN; Kwekkeboom J; van der Laan LJ
Transpl Infect Dis; 2015 Oct; 17(5):707-15. PubMed ID: 26250892
[TBL] [Abstract][Full Text] [Related]
2. Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα.
Serti E; Park H; Keane M; O'Keefe AC; Rivera E; Liang TJ; Ghany M; Rehermann B
Gut; 2017 Apr; 66(4):724-735. PubMed ID: 26733671
[TBL] [Abstract][Full Text] [Related]
3. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
Nagaoki Y; Imamura M; Aikata H; Daijo K; Teraoka Y; Honda F; Nakamura Y; Hatooka M; Morio R; Morio K; Kan H; Fujino H; Kobayashi T; Masaki K; Ono A; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Hayes CN; Miki D; Ochi H; Chayama K
PLoS One; 2017; 12(8):e0182710. PubMed ID: 28797106
[TBL] [Abstract][Full Text] [Related]
4. Quantification and functional analysis of plasmacytoid dendritic cells in patients with chronic hepatitis C virus infection.
Goutagny N; Vieux C; Decullier E; Ligeoix B; Epstein A; Trepo C; Couzigou P; Inchauspe G; Bain C
J Infect Dis; 2004 May; 189(9):1646-55. PubMed ID: 15116301
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
[TBL] [Abstract][Full Text] [Related]
6. Effective Treatment With Daclatasvir and Asunaprevir in Kidney Transplant Patients Infected With Hepatitis C Virus: A Report of Two Cases.
Koshino K; Ushigome H; Masuda K; Matsuyama T; Harada S; Nakamura T; Nobori S; Iida T; Yoshimura N
Transplant Proc; 2017 Jun; 49(5):1053-1055. PubMed ID: 28583525
[TBL] [Abstract][Full Text] [Related]
7. Toll-Like Receptor 7 (TLR-7) and TLR-9 Agonists Improve Hepatitis C Virus Replication and Infectivity Inhibition by Plasmacytoid Dendritic Cells.
Dominguez-Molina B; Machmach K; Perales C; Tarancon-Diez L; Gallego I; Sheldon JL; Leal M; Domingo E; Ruiz-Mateos E
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232187
[TBL] [Abstract][Full Text] [Related]
8. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
[TBL] [Abstract][Full Text] [Related]
9. Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.
Barrail-Tran A; Vincent C; Furlan V; Rosa I; Rosenthal E; Cheret A; Molina JM; Taburet AM; Piroth L;
Antimicrob Agents Chemother; 2015 Dec; 59(12):7903-5. PubMed ID: 26438504
[TBL] [Abstract][Full Text] [Related]
10. Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment.
Spaan M; van Oord G; Kreefft K; Hou J; Hansen BE; Janssen HL; de Knegt RJ; Boonstra A
J Infect Dis; 2016 Jan; 213(2):216-23. PubMed ID: 26223768
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.
Toyoda H; Kumada T; Tada T; Takaguchi K; Ishikawa T; Tsuji K; Zeniya M; Iio E; Tanaka Y
J Gastroenterol; 2016 Jul; 51(7):741-7. PubMed ID: 26872889
[TBL] [Abstract][Full Text] [Related]
12. Ribavirin Contributes to Hepatitis C Virus Suppression by Augmenting pDC Activation and Type 1 IFN Production.
Wang Y; McGivern DR; Cheng L; Li G; Lemon SM; Niu J; Su L; Reszka-Blanco NJ
PLoS One; 2015; 10(8):e0135232. PubMed ID: 26274905
[TBL] [Abstract][Full Text] [Related]
13. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection.
Yang SS; Kao JH
Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):9-20. PubMed ID: 25174254
[TBL] [Abstract][Full Text] [Related]
14. Decreased CD4
Wei K; Jiang BC; Guan JH; Zhang DN; Zhang MX; Wu JL; Zhu GZ
Viral Immunol; 2018 Oct; 31(8):559-567. PubMed ID: 30067145
[TBL] [Abstract][Full Text] [Related]
15. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
[TBL] [Abstract][Full Text] [Related]
16. Asunaprevir (BMS-650032) for the treatment of hepatitis C virus.
Akamatsu N; Sugawara Y; Kokudo N
Expert Rev Anti Infect Ther; 2015; 13(11):1307-17. PubMed ID: 26414905
[TBL] [Abstract][Full Text] [Related]
17. Are statins a viable option for the treatment of infections with the hepatitis C virus?
Verpaalen B; Neyts J; Delang L
Antiviral Res; 2014 May; 105():92-9. PubMed ID: 24613180
[TBL] [Abstract][Full Text] [Related]
18. The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir.
Hayes CN; Imamura M; Chayama K
Expert Rev Gastroenterol Hepatol; 2017 Feb; 11(2):103-113. PubMed ID: 27936974
[TBL] [Abstract][Full Text] [Related]
19. Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection.
Zeuli JD; Adie SK; Rizza SA; Temesgen Z
Drugs Today (Barc); 2015 Nov; 51(11):629-43. PubMed ID: 26744738
[TBL] [Abstract][Full Text] [Related]
20. The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host.
Braun M; Vierling JM
Liver Transpl; 2003 Nov; 9(11):S79-89. PubMed ID: 14586901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
